Advanced photodynamic therapy with an engineered M13 phage targeting EGFR: Mitochondrial localization and autophagy induction in ovarian cancer cell lines

Bortot, Barbara; Apollonio, Maura; Baj, Gabriele; Andolfi, Laura; Zupin, Luisa; Crovella, Sérgio; Giosia, Matteo Di; Cantelli, Andrea; Saporetti, Roberto; Ulfo, Luca; Petrosino, Angelo; Lorenzo, Giovanni Di; Romano, Federico; Ricci, Giuseppe; Mongiat, Maurizio; Danielli, Alberto; Calvaresi, Matteo; Biffi, Stefania

doi:10.1016/j.freeradbiomed.2021.11.019

Cited by 27 publications

(25 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This evidence points out the usefulness of HSA formulation for chemotherapeutic drugs and mTHPC@HSA perfectly fits in this context. Moreover, the performances of the mTHPC@HSA platform can be additionally improved by using light-harvesting antennae to extend the PDT activity of the mTHPC into the NIR [66], or by attaching targeting moieties to specifically address cellular receptors that are usually overexpressed in cancer cells for receptor-targeted PDT [67][68][69][70][71].…”

Section: Discussionmentioning

confidence: 99%

Carrying Temoporfin with Human Serum Albumin: A New Perspective for Photodynamic Application in Head and Neck Cancer

et al. 2022

View full text Add to dashboard Cite

Temoporfin (mTHPC) is approved in Europe for the photodynamic treatment of head and neck squamous cell carcinoma (HNSCC). Although it has a promising profile, its lipophilic character hampers the full exploitation of its potential due to high tendency of aggregation and a reduced ROS generation that compromise photodynamic therapy (PDT) efficacy. Moreover, for its clinical administration, mTHPC requires the presence of ethanol and propylene glycol as solvents, often causing adverse effects in the site of injection. In this paper we explored the efficiency of a new mTHPC formulation that uses human serum albumin (HSA) to disperse the photosensitizer in solution (mTHPC@HSA), investigating its anticancer potential in two HNSCC cell lines. Through a comprehensive characterization, we demonstrated that mTHPC@HSA is stable in physiological environment, does not aggregate, and is extremely efficient in PDT performance, due to its high singlet oxygen generation and the high dispersion as monomolecular form in HSA. This is supported by the computational identification of the specific binding pocket of mTHPC in HSA. Moreover, mTHPC@HSA-PDT induces cytotoxicity in both HNSCC cell lines, increasing intracellular ROS generation and the number of γ-H2AX foci, a cellular event involved in the global response to cellular stress. Taken together these results highlight the promising phototoxic profile of the complex, prompting further studies to assess its clinical potential.

show abstract

Section: Discussionmentioning

confidence: 99%

Carrying Temoporfin with Human Serum Albumin: A New Perspective for Photodynamic Application in Head and Neck Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…36 The killing effect of Ce6-PDT on cells became stronger as the photosensitizer concentration increased, and at 8.0 g/mL, the apoptosis rate of SW260 exceeded 60%. Other studies have shown that Ce6 photodynamic therapy can treat triple-negative breast cancer, 37 brain cancer, 38 ovarian cancer, 39 and colon cancer. 40 2.3.…”

Section: Applications Of Ce6 In Photodynamic Therapymentioning

confidence: 99%

Antitumor Effect of Photodynamic Therapy/Sonodynamic Therapy/Sono-Photodynamic Therapy of Chlorin e6 and Other Applications

et al. 2023

View full text Add to dashboard Cite

Chlorin e6 (Ce6) has been extensively researched and developed as an antitumor therapy. Ce6 is a highly effective photosensitizer and sonosensitizer with promising future applications in photodynamic therapy, dynamic acoustic therapy, and combined acoustic and light therapy for tumors. Ce6 is also being studied for other applications in fluorescence navigation, antibacterials, and plant growth regulation. Here we review the role and research status of Ce6 in tumor therapy and the problems and challenges of its clinical application. Other biomedical effects of Ce6 are also briefly discussed. Despite the difficulties in clinical application, Ce6 has significant advantages in photodynamic therapy (PDT)/sonodynamic therapy (SDT) against cancer and offers several possibilities in clinical utility.

show abstract

“…The same EGFR-targeting vector was conjugated with chlorin e6 (Ce6) instead of Rose Bengal [249]. Upon laser irradiation (660 nm, irradiance 50 mW/cm 2 ), this new phage platform was able to generate ROS via the type I mechanism and to kill SKOV3 and COV362 ovarian cancer cells, even at concentrations at which Ce6 alone was ineffective.…”

Section: Refactored Anti-egfr Phagesmentioning

confidence: 99%

EGFR-Targeted Photodynamic Therapy

et al. 2022

Self Cite

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) plays a pivotal role in the proliferation and metastatization of cancer cells. Aberrancies in the expression and activation of EGFR are hallmarks of many human malignancies. As such, EGFR-targeted therapies hold significant potential for the cure of cancers. In recent years, photodynamic therapy (PDT) has gained increased interest as a non-invasive cancer treatment. In PDT, a photosensitizer is excited by light to produce reactive oxygen species, resulting in local cytotoxicity. One of the critical aspects of PDT is to selectively transport enough photosensitizers to the tumors environment. Accordingly, an increasing number of strategies have been devised to foster EGFR-targeted PDT. Herein, we review the recent nanobiotechnological advancements that combine the promise of PDT with EGFR-targeted molecular cancer therapy. We recapitulate the chemistry of the sensitizers and their modes of action in PDT, and summarize the advantages and pitfalls of different targeting moieties, highlighting future perspectives for EGFR-targeted photodynamic treatment of cancer.

show abstract

Advanced photodynamic therapy with an engineered M13 phage targeting EGFR: Mitochondrial localization and autophagy induction in ovarian cancer cell lines

Cited by 27 publications

References 62 publications

Carrying Temoporfin with Human Serum Albumin: A New Perspective for Photodynamic Application in Head and Neck Cancer

Carrying Temoporfin with Human Serum Albumin: A New Perspective for Photodynamic Application in Head and Neck Cancer

Antitumor Effect of Photodynamic Therapy/Sonodynamic Therapy/Sono-Photodynamic Therapy of Chlorin e6 and Other Applications

EGFR-Targeted Photodynamic Therapy

Contact Info

Product

Resources

About